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a b s t r a c t 
Purpose: Hydrocephalus is a major cause of morbidity in the pediatric population, with 
potentially severe consequences if left untreated. Two viable strategies for management of 
non-communicating hydrocephalus are endoscopic third ventriculostomy (ETV) and 
ventriculoperitoneal shunting. However, there is uncertainty over the safety and efficacy of 
ETV in younger infants aged 1 year or below. In this systematic review, we aim to elucidate 
the success rate and procedural risks of ETV in this age group. 
Methods: A multi-database (PubMed, Embase, Web of Science) literature search between 
January 1990 and April 2018 was performed in accordance with PRISMA guidelines. Eligible 
studies were included if they (i) examined non-communicating hydrocephalus; (ii) quantified 
the success/failure rates of ETV; and (iii) assessed outcomes in children 1 year of age or 
younger. 
Results: A total of 19 articles with 399 patients were eligible for inclusion. Mean age at 
procedure was 4.2 months (range 34 weeks gestation to 12 months), with 116 females and 
143 males. Commonest underlying aetiology was congenital aqueductal stenosis (AS) 
(60.4%). Remaining causes included posthaemorrhagic, post-infection, Chiari malformations, 
malignancies and others. Overall and AS mean success rates were 51.6% and 56.5% 
respectively. Overall complication rate was 10.0%, consisting mainly of CSF leak, infection, 
and haemorrhage. Younger age was significantly associated with poorer ETV success 
rate when divided into <6 months and 6e12 months of age (44.4 vs 66.7%; p ¼ 0.0007). 
Underlying pathology had no significant association with ETV outcome when divided into AS 
and other pathologies (p ¼ 0.53). 
Conclusions: Age is significantly associated with ETV success rates. Pathology-dependent 
effects were not found in this age group. Despite a lower ETV success rate at younger ages 
(44.4 vs 66.7%), it offers a comparable safety profile that is independent of age. ETV remains 
a viable treatment option for noncommunicating hydrocephalus for infants aged 1 year or 
younger. 
 
1. Introduction 
Hydrocephalus is a major cause of morbidity in the paediatric population, with an estimated 
prevalence of 1.2 in every 1000 children [1]. It is estimated to account for approximately 
half of all paediatric neurosurgical cases managed in the UK [2]. In children, untreated 
hydrocephalus can have severe consequences including developmental problems, learning 
difficulties, and blindness [3]. Hydrocephalus can be classified as communicating or 
noncommunicating, depending on the level of obstruction to CSF flow. This classificationwas 
first proposed byWalter Dandy in 1918 [4], and the distinction between the two categories 
was related to exit of CSF from the fourth ventricle. 
 
Traditionally, shunts have been used as the main treatment strategy for both 
communicating and non-communicating hydrocephalus. More recently, endoscopic third 
ventriculostomy (ETV) has emerged as a method of treatment for hydrocephalus [3,5]. The 
first ETV was actually performed in 1923 by the urologist, William Mixter, who performed 
the procedure on a child with obstructive hydrocephalus using a urethroscope [6]. However, 
this procedure was not widely adopted until the 1980's, when advancements in equipment 
ensured that itwas safer/more successful [7]. Shunts are associated with significant 
complications, such that they are thought to occur in close to40% of shunted patients, and 
they include failure and infection [8,9]. In contrast, ETV, which does not involve the 
insertion of foreign bodies into the central nervous system (CNS), is associated with a lower 
complication rate (<10%) [10]. 
 
Currently, both ETV and shunting are viable strategies for treating non-communicating 
hydrocephalus. While patient age is believed to be an important factor when it comes to 
shunting, it is not entirely clear if there is a cut-off age below which ETV cannot be 
performed safely and, if so, what that is [11]. Much controversy remains over whether 
children younger than 1 year of age are at greater risk of ETV failure/complications 
compared with older patients [12]. The aim of this studywas to perform a systematic 
review/ meta-analysis on the published literature on ETV in children aged 1 year or younger, 
in order to elucidate the success rate of this procedure in this particular patient population. 
 
2. Methods 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
Statement was used to prepare this paper [13]. The protocol for this systematic review is 
registered on PROPSERO (CRD42018081949). 
 
2.1. Literature search 
A multi-database (PubMed, Embase, Web of Science) literature search between January 
1990 and April 2018 was performed by authors SM and AH. Conflict of opinionwas settled 
by senior author PL. The search terms used were: non-communicating/obstructive 
hydrocephalus AND ;͞eŶdoscopic third veŶtriculostoŵy͟ or ETVͿ AND (child OR children OR 
infants). Only articles in English were included in the search. The bibliographies of identified 
papers were examined in order to identify any further relevant articles. 
 
2.2. Literature selection 
Articles were identified according to the aforementioned criteria, and all titles and abstracts 
were reviewed. Eligible studies were included if they satisfied all of the following criteria: (1) 
examine non-communicating/obstructive hydrocephalus; (2) quantify the success/failure 
rates of ETV; and (3) assess outcome in children 1 year of age or younger. Underlying 
pathology was also noted. In cases where pathologies typically associated with 
communicating hydrocephalus were present, patients were still included if the article 
categorized them as obstructive. Any uncertainties were resolved by discussion with the 
senior author (PL). 
 
2.3. Data extraction/analysis 
The following data were extracted from the selected papers by authors SM and FS: (1) 
number of subjects; (2) mean age of patients; (3) sex of patients; (4) the underlying 
aetiology of the noncommunicating hydrocephalus; (5) the exact intervention performed; 
(6) the number of successful cases; (7) the percentage of successful cases; (8) average time 
at follow-up; (9) number of cases in which complications were recorded; and (10) the 
percentage of cases in which complications were recorded. ETV success was defined as the 
avoidance of VP shunting in our analyses, consistent with the majority of studies (see 
Results). Meta-analysis was performed using Microsoft Excel v16.24, using the Chi square 
test to evaluate the effects of underlying pathology and age on ETV success. 
 
2.4. Assessment for bias 
Risk of bias was analyzed by three senior authors (MZ, CP, and IB) using the risk of bias in 
non-randomized studies e of interventions (ROBINS-I) assessment tool [14] (see Table 1). 
 
3. Results 
A total of 629 articles were generated. Four additional articles were identified upon 
reviewing bibliographies of relevant articles. In total, 614 articles were excluded, thus 
leaving 19 articles for subsequent analysis (see Fig. 1). The reasons for exclusion were: (1) 
articles were not original research; (2) did not feature noncommunicating hydrocephalus or 
also featured communicating hydrocephalus; (3) did not consider patients 1 year of age or 
younger; and/or (4) considered choroid plexus cauterization (CPC) combined with ETV as a 
treatment for hydrocephalus. Two studies were extensions of previous publications from 
the same group, therefore only one of each was included for further analysis, based on 
meaningful data regarding demographics and outcome elucidated in each study [15,16]. 
 
 
 
3.1. Demographics 
In total, 19 studies [15e33] were eligible for final inclusion (see Table 2). A total of 399 
patients were evaluated. The mean ageacross 190 patients, where age was individually 
stated, was 4.2 months (range 34 weeks gestation to 12 months). Of the 256 patients whose 
genders were stated, 116 were female while 143 were male. The most common underlying 
aetiology of the noncommunicating hydrocephalus was congenital aqueductal stenosis, 
which accounted for 50% of all cases (177 out of 399). Remaining causes of hydrocephalus 
included post-haemorrhagic (35; 8.8%), post-infection (83; 20.8%), Chiari malformation (16; 
4.0%), malignancy (6; 1.5%), Dandy Walker malformation (5; 1.3%), intracranial cysts (5; 
1.3%), myelomeningocele (3; 0.8%), CNS malformation (2; 0.5%), Galen malformation and 
occipital encephalocele (1; 0.3% each). Aetiology was unspecified in 11.8% of patients 
(47 patients). 
 
 
 
 
3.2. ETV outcomes 
ETV was the first surgical procedure in the majority of patients (385; 96.5%). Of the patients 
with prior failed procedures, 1 patient had an aqueductoplasty, and the remaining 13 
patients had VP shunts. In 0.8% of cases (3 out of 399 cases), ETVwas combined with 
endoscopic cystocisternostomy (ECC). Included studies had minor variation on their 
definition of success, but avoidance of shunting was the predominant theme (see Table 3). 
The mean success rate across all patients was 51.6% (206 out of 399 cases). Mean success 
rate in primary aqueductal stenosis was 56.5% (100 out of 177 cases), whilst other 
pathologies had a mean success rate of 53.1% (93 out of 175 cases) (see Table 4). However, 
underlying pathology had no significant association with ETV outcome (Chi sq test, pvalue 
0.53, see below). 
 
Out of 399 patients, only 40 (10.0%) were reported to have post-operative complications, 
outside of procedural failure. The complications, in descending order of prevalence, were: 
postoperative pyrexia (10; 25%); CSF leak (6; 15%); meningitis (4; 10%); subdural 
haematoma, wound infection, oculomotor nerve palsy, and intra-ventricular haemorrhage 
(3; 7.5%); diabetes insipidus (2; 5%); abducens nerve palsy, transient hyponatraemia, CSF 
fistula, transient Parinaud's syndrome, seizures, and forniceal injury (1; 2.5% each). Duration 
of follow up was reported for 207 patients, with an average duration of 27.0 months (range 
1 weeke106 months). 
 
3.3. Risk factors 
Age was significantly associated with ETV outcomes when divided into <6 months and 6e12 
months of age (Chi sq 11.6, Df 1, p-value 0.0007) (see Table 5), demonstrating better 
outcomes in the older age group. Underlying pathology had no significant association with 
ETV outcome when comparing primary aqueductal stenosis with other pathologies (Chi sq 
0.40, Df 1, p-value 0.53). 
 
4. Discussion 
Neurosurgical reports on which patients are most expected to benefit from ETV are ample 
and contradictory. The debate largely focuses on the success rates, the influence of age, 
aetiology or both. Some neurosurgeons advocate ETV as the treatment of choice for non-
communicating hydrocephalus caused by primary aqueductal stenosis and other selected 
pathologies [34]. Indeed, ETV was performed as a first line procedure in 96.5% of patients 
included in this study. However, whether children younger than 1 year of age are at greater 
risk of ETV failure compared with older patients remains contentious. 
 
The mean success rate was 51.6% across all included studies. Reported success rates across 
included studies ranged from 0% [29] to as high as 83% [25]. Some studies found lower 
success rates in younger patients [20,30,32], although the differences were not always 
statistically significant [16,25,35]. One study found a pathology dependent effect rather 
than an age dependent effect on outcomes of ETV, where patients with congenital aqueduct 
stenosis had better outcomes than other categories [22]. Both an age and aetiology 
dependent outcome were reported by four studies [24,26,28],39. One study found that 
younger patients with aqueductal stenosis and Chiari malformation had statistically 
significant worse outcomes [24]. The remaining studies found that older infants with 
aqueductal stenosis yielded better outcomes [26,28]. However, statistical analyses were not 
performed, likely due to the small sample size, which was acknowledged by the authors.  
 
Kulkarni et al. developed the ETV Success Score (ETVSS) in children [36]. This prediction 
model provides a simple method for predicting success of ETV at 6 months. The score is 
based on 3 factors; listed in order of magnitude: patient age, aetiology of hydrocephalus, 
and the presence or absence of a previous shunt. The highest rate of success is found in 
older children with aqueduct stenosis or tectal tumor who have not had previous shunting. 
The ETVSS has been externally validated in a number of studies [37e39]. However, ETV still 
fails in certain patients, despite being the best candidates for the procedure according to 
the prediction model [40]. 
 
Success rates were notably lower in earlier studies. As with any procedure, a learning curve 
is expected. It is possible that a gradual improvement in outcomes will occur as the 
cumulative experience increases over time. Operative details were notably absent in 7 of 
the 18 studies. Future studies are advised to report on surgical details, as they may be vital 
in determining success of ETV. 
 
Despite encompassing a relatively large number of patients (n ¼ 399), included studies 
demonstrate both clinical and methodological heterogeneity. For example, there is 
variability in the definition of successful outcomes, length of follow up, surgical technique 
and diagnostic imaging used. All studies except two were found to have critical or serious 
risks of bias. The two exceptions encompassed 60 patients (20.4% of total). Also, the 
majority of studies were of retrospective design. Methodological concerns common to 
retrospective studies include selection bias, publication bias and incomplete data. 
 
 
 
An important issue to consider when deciding whether ETV is a suitable treatment option in 
children aged one year or under is its cost compared to other techniques. A study examining 
the cost/ benefit ratio of ETV compared with shunting found no statistically significant 
difference between the two treatment strategies, though there was a trend towards an 
improved cost/benefit ratio with ETV compared with shunting [1]. However, further studies, 
focusing on the patient cohort that this review examined, are required to determine 
whether ETV is a cost-effective treatment option for hydrocephalus in this particular patient 
group. 
  
 
This systematic review has a number of limitations. Firstly, by excluding articles published in 
languages other than English, it may be that a number of relevant articles were missed. 
Similarly, the search terms we used may have limited the number of articles that the search 
generated, therefore resulting in omission of some relevant articles. However, examination 
of the bibliographies of relevant articles only brought up a further four articles that were 
included in the review. One key issue was defining ETV success, which varied between 
included articles (Table 3). Given that the majority of articles included the absence of 
requirement for VP shunt insertion as a criterion for ETV success, we adopted this in the 
evaluation of the cohort. Although this dichotomization is pragmatic, variability in the 
duration of follow up affects the validity of this measure. Indeed, whilst the mean follow-up 
period was 27 months, a wide range was reported, from 1 week to 106 months. Therefore, 
it is difficult to determine the long term outcomes of ETV in our chosen patient population, 
given that ETV failure is thought to increase with longer follow up periods [5]. Future studies 
require longer duration of follow up and stricter definitions for ETV success in this age 
group. A further limitation of this systematic review is the fact that, while the majority of 
patients underwent ETV alone, a small minority underwent ETV coupled with ECC. ECC is 
likely to alter the efficacy of ETV when compared with ETV alone, which may hinder direct 
comparisons. Finally, more than half of the cases included in this review were due to 
primary aqueductal stenosis, with a much smaller proportion resulting from other 
aetiologies. For instance, the inclusion of infants with malignant brain tumours and the 
associated poor prognosis may skew the proposed ETV success rate. This limits the validity 
of this systematic review in determining the efficacy of ETV as a treatment for 
noncommunicating hydrocephalus secondary to etiologies other than aqueductal stenosis. 
Finally, it should be noted that some potentially eligible patients may have been excluded as 
part of a subgroup with insufficient data, restricting the cohort that was studied. 
 
5. Conclusion 
Our systematic review shows that ETV is successful in just over half of all included cases of 
non-communicating hydrocephalus. Despite higher success rates for aqueductal stenosis at 
56.5%, we found no statistically significant pathology-dependent effect on ETV success rate. 
We report an overall complications rate of 10.0%, with CSF leak, haemorrhage, and infection 
being the most frequently encountered complications. Despite a lower success rate 
at younger ages, ETV offers a comparable safety profile that is independent of age. 
Therefore, ETV may remain a viable treatment option for non-communicating 
hydrocephalus for infants aged 1 year or younger. 
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